An important discovery in mice may make a big difference in people’s waistlines thanks to a team of Harvard scientists who found that reducing the function of a transmembrane protein, called Klotho, in obese mice with high blood sugar levels produced lean mice with reduced blood sugar levels. This protein also exists in humans, suggesting that selectively targeting Klotho could lead to a new class of drugs to reduce obesity and possibly Type 2 diabetes for people. This finding was recently published online in The FASEB Journal (http://www.fasebj.org).
“Our study is a small step toward reducing the sufferings of obese and diabetic individuals to bring back the joy of healthy life,” said M. Shawkat Razzaque, M.D., Ph.D., a researcher involved in the work from the Department of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine in Boston. “In the dark horizon of obesity and diabetes, Klotho brings a ray of hope.”
To make this discovery, Razzaque and colleagues fed increased amounts of food to leptin-deficient mice with the Klotho protein which caused obesity with high blood sugar levels. A second set of mice was bred that was both leptin- and Klotho-deficient, and was fed the same diet as the first set. The second set of mice was lean and had low blood sugar levels, suggesting that reduced Klotho function may not only diminish obesity, but also decrease blood sugar levels. Furthermore, mice without Klotho function gained no body weight after eating a high-fat diet, while mice with functioning Klotho proteins gained body weight following a high-fat diet.
“In Greek mythology, Klotho was the youngest of three fates, the one responsible for spinning the thread of life; since then we have learned that obesity cuts the thread short,” said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. “It’s good to know that the new molecular biology of Klotho points to agents that will keep us fit and well-spun.”
Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB) and celebrates its 25th anniversary in 2011. Over the past quarter century, the journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information.
FASEB comprises 23 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve — through their research — the health, well-being and productivity of all people. FASEB’s mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Mutsuko Ohnishi, Shigeko Kato, Junko Akiyoshi, Azeddine Atfi, and M. Shawkat Razzaque. Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J fj.10-167056; doi:10.1096/fj.10-167056 ; http://www.fasebj.org/content/early/2011/03/07/fj.10-167056.abstract
